Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05500170 · ClinicalTrials.gov registry record · NA
Benefits of Nicotinamide Riboside Upon Cognition and Sleep
A NA study of Cognitive Impairment and Sleep Quality, sponsored by State University of New York at Buffalo.
- Recruiting
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 3
- Study locations
NCT05500170 is a NA study of Cognitive Impairment and Sleep Quality that is actively recruiting participants, run by State University of New York at Buffalo. The registered enrollment target is 50 participants, below the 665-participant average among 105 other Cognitive Impairment trials with a reported enrollment target (92% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT05500170, a NA study of Cognitive Impairment and Sleep Quality, is actively recruiting participants, sponsored by State University of New York at Buffalo.
- RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 3
- Study locations
Study Summary
Poor sleep quality and short sleep duration may be a mechanistic component of cognitive impairment in older adults, associated with a decline in brain-derived neurotrophic factor. Increasing the availability of nicotinamide adenine dinucleotide (NAD+) with supplementation of its precursor, nicotinamide riboside (NR), a form of vitamin B3 may increase the expression of brain-derived neurotrophic factor. This study proposes to examine the benefits of NR supplementation on sleep and cognitive function in older adults with comprehensive subjective and objective measures and to explore its impacts on serum brain-derived neurotrophic factor.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Nicotinamide riboside
Study Locations (3)
New York
- State University of New York at Buffalo - Buffalo
- University at Buffalo State University of New York - Buffalo
- Buffalo Veteran Affairs Medical Center - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-04-04 |
| Est. Completion | 2027-08-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05500170
The ClinicalTrials.gov registry entry for NCT05500170 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 665-participant average among 105 other Cognitive Impairment trials with a reported enrollment target (92% lower). The listed sponsor is State University of New York at Buffalo, which has 243 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cognitive Impairment appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05500170 reports 3 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05500170 about?
NCT05500170 is a clinical study titled "Benefits of Nicotinamide Riboside Upon Cognition and Sleep". Poor sleep quality and short sleep duration may be a mechanistic component of cognitive impairment in older adults, associated with a decline in brain-derived neurotrophic factor. Increasing the availability of nicotinamide adenine dinucleotide (NAD+) with supplementation of its precursor, nicotinam...
What is the current status of trial NCT05500170?
This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2023-04-04. Estimated completion is 2027-08-30.
What conditions does trial NCT05500170 study?
This clinical trial studies the following conditions: Cognitive Impairment, Sleep Quality.
What interventions are being tested in trial NCT05500170?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Nicotinamide riboside (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05500170?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05500170 being conducted?
This trial has 3 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS
RECRUITING · NA
-
Mind Your Heart-II
RECRUITING · NA
-
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
RECRUITING · NA
-
Impact of a Multimodal Lifestyle Intervention on Dementia Risk Factors and Attitude Related to Dementia Risk: A Logistical Pilot Study
RECRUITING · NA
-
Essential Fats For Enhancing Cognitive Thinking (EFFECT) Study
RECRUITING · NA
-
Amygdala Memory Enhancement
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.